What is OmniLytics?
OmniLytics, Inc. operates at the intersection of advanced microbiology and agricultural science, specializing in the development of eco-friendly bacteriophage solutions. By targeting harmful pathogens across crop science, food safety, and animal health, the company provides a robust alternative to conventional antibiotics and chemical pesticides. Their flagship AgriPhage product line is engineered to enhance agricultural yields while mitigating the ecological footprint of bacterial disease management. Beyond its core product offerings, OmniLytics leverages its advanced GMP-certified manufacturing facility to provide contract production services, ensuring that high-quality, phage-based interventions are accessible for large-scale industrial applications. This dual-pronged approach of product innovation and manufacturing excellence establishes the company as a critical player in the global transition toward sustainable food systems.
How much funding has OmniLytics raised?
OmniLytics has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in OmniLytics
PPP
Public-Private Partnership
What's next for OmniLytics?
Following this late-stage capital infusion, OmniLytics is expected to prioritize the expansion of its commercial footprint and the optimization of its manufacturing capabilities. The strategic allocation of these funds will likely support the scaling of its AgriPhage distribution networks and the further refinement of its biological pathogen control platforms. As the global regulatory landscape increasingly favors non-chemical interventions, OmniLytics is poised to capture significant market share by addressing the urgent demand for safe, effective, and sustainable disease management solutions in the agricultural and food safety sectors. Future growth will likely be driven by continued investment in R&D and the potential for strategic partnerships to broaden the application of its proprietary phage technology.
See full OmniLytics company page
